In a therapeutic perspective, wecompared the outcomes of specific neuronal or astrocytic CYP46A1 targeting to those of a combined strategy using a strong ubiquitous CAG promoter, as previously tested in the R6/2 and the zQ175 mouse models of HD. This evidence concerns the gene CYP46A1 and Huntington disease.